Postby GrouseMan » Sun Nov 22, 2015 11:12 pm
If you want to know ask, and don't accept no for an answer. It comes down to that. You must be your own advocate! But doctors are not going to be know for certain anything concerning time left, severity of side effects with chemo, or other QOL issues. As you said they don't have a crystal ball. The difference between Cancer, and Heart Disease, Diabetes, COPD, high blood pressure, high LDL, is that I think the doctors have a little better understanding of the effects of these diseases. Generally they don't mutate and change over time, or spread, and effect other organs, or systems like cancer can. Probably the only other disease that is as intractable as cancer is Alzheimer, and unlike cancer, there really at this time no effective treatments in my opinion. Pharmaceutical companies have spent billions on research and have practically nothing to show for it.
Everyone's cancers are different. That is because everyone's DNA and genetics are different. Everyone's multiple mutations that enables them to develop cancers are unique to that person. To be sure there are many similarities. Gross pathological types for example, Breast, Colon, Lung, Hematological, Lymphomas, etc. Within the gross types, there usually are some commonalities. Kras, Braf, EGFr, are common mutations in colon cancer. MSS, MSI status. Even different Mets from their primary will be different from one site in you body vs another. So if you could actually examine every met, and the primary for all their mutations you will find that everyone's mutation profile is likely very different with some commonalities. The various drugs are going to be effective with some, no so effective with others, and the terrible thing is that any new met likely will have mutated further such that different drugs will need to be tried.
The problem is, there are limitations to full genetic profiling. You need enough sample from each met you want to try and treat, in order to select the best drug candidate to treat it. This isn't always possible. You might not get a good representative sample. Even within a single tumor different layers of tumor cells might have different sets of mutations. Also, detailed genetic profiling isn't at all like its shown on TV. It takes time to do the genetic testing. The more detailed the longer it takes. Most tests that are done only look for the most common. They might not even be able to say what the specific amino acid transposition is. As a result oncologists can only make educated guesses. Some do a better job than others.
Now that said. I was a drug researcher for 21 years, most of that time doing Anticancer drug research. I was involved in some of the very first anticancer kinase inhibitors, prior to that I worked on cytotoxic drugs including topoisomerase inhibitors, platinum complexes, and DNA binding drug. In the last 10 years we have learned so much more than in the previous 30 years I believe. The revolution in immunotherapy that is occurring is making the future look brighter than I have ever seen it. A combination of that and new combination chemo drugs including new kinase inhibitors that act selectively against mutant protein receptors may help finally turn the corner. This is a marathon. The goal is to hang in there as best you can to turn the corner with these treatments.
Good luck
GrouseMan
DW 53 dx Jun 2013
CT mets Liver Spleen lung. IVb CEA~110
Jul 2013 Sig Resct
8/13 FolFox,Avastin 12Tx mild sfx, Ongoing 5-FU Avastin every 3 wks.
CEA: good marker
7/7/14 CT Can't see the spleen Mets.
8/16/15 CEA Up, CT new abdominal mets. Iri, 5-FU, Avastin every 2 wks.
1/16 Iri, Erbitux and likely Avastin (Trial) CEA going >.
1/17 CEA up again dropped from Trial, Mets growth 4-6 mm in abdomen
5/2/17 Failed second trial, Hospitalized 15 days 5/11. Home Hospice 5/26, at peace 6/4/2017